Consent given pursuant to sections 14 and 14A for the supply and importation of the Therapeutic Goods specified subject to conditions specified - between 20 May 2014 and 20 May 2015

Administered by Department of Health, Disability and Ageing

Legislation au C2014G01219 In force Gazette

Legislation content

COMMONWEALTH OF AUSTRALIA

Department of Health
Therapeutic Goods Administration

THERAPEUTIC GOODS ACT 1989

Section 14 and 14A Notice

 

 

On May 20 2014, the delegate of the Secretary of the Department of Health for the purposes of subsection 14 and 14A of the Therapeutic Goods Act 1989 (“the Act”), by application of Aspen Pharmacare Australia Pty Ltd, gave consent to:

The importation and supply of danaparoid sodium (ORGARAN) 750 anti-Xa units per 0.6 mL injection ampoule [AUST R 46096] that does not conform with the requirements of paragraph 3(2)(l) of the Therapeutic Goods Order No. 69- General requirements for labels for medicines in that the labels state the previous sponsor contact details.

 

The consent is effective from May 20, 2014 until May 20, 2015.

The delegate of the Secretary has, under subsection 15(1) of the Act, made the consent subject to the following conditions:

  1. The labels are those currently supplied which state the previous sponsor;
  2. Arrangements are in place to redirect all correspondence to the current sponsor (Aspen); and
  3. No other changes have been made.

 

 

 

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.